Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2010

View Archived Issues

Netupitant shows promise to treat overactive bladder in preclinical studies

Researchers describe new anti-inflammatory MAPK 14 inhibitors

NGP-328 is selected as clinical candidate for Alzheimer's disease

Stem cell research funding ban does not affect International Stem Cell

SuperGen discovers new inhibitors of tyrosine-protein kinase receptor UFO

Wyeth claims new cannabinoid CB2 receptor agonists

Recordati discloses new metabotropic glutamate mGlu5 receptor antagonists

FDA accepts Sanofi Pasteur's BLA to expand Menactra indication

Organon identifies new TRPV1 ligands

Taisho Pharma describes new histamine H3 receptor antagonists

NIH renews research funding for Homspera in radiation-induced lung injury

Pharming prepares to submit Rhucin BLA to FDA

FDA approves phase II trial protocol of CH-4051 in rheumatoid arthritis

Shire's VPRIV approved in Europe for type 1 Gaucher's disease

Vanda Pharma begins phase III tasimelteon trial in blind patients with N24HSWD

Lotus Pharma initiates phase I trial of (R)-bambuterol in China

FDA issues refuse to file letter for trastuzumab-DM1 BLA

Cardioxyl begins phase IIa trial of CXL-1020 for heart failure

DIDS improves yield and preserves integrity of isolated pancreatic islets

Karo Bio reviews phase III eprotirome program in hypercholesterolemia

Octapharma USA voluntarily withdraws lots of Octagam 5% from market

Actelion to exclusively distribute Basilea's Toctino in Canada

FDA grants orphan drug status to Kineret in CAPS

LIM-0705 reverses tacrolimus-induced metabolic defects in phase Ib trial

FDA approves Novartis' Tekamlo for hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...